QNCX (Quince) Earnings growth in current year

QNCX (Quince Therapeutics) - company brandmark

Quince Therapeutics (QNCX) is developing unique erythrocyte-based drug delivery systems to combat metabolic disorders. The relative EPS YoY trend demonstrates a smooth business recovery, with 0.00 serving as the current metric level. The efficiency of the R&D platform will enable the monetization of patents through royalties, while the acquisition of oncology assets mitigates the risks associated with a narrow development profile.

QNCX: quincetx.com Earnings per share growth in current year 04/28/2023 - 10/12/2026

Financial and market metric breakdowns for Quince Therapeutics (QNCX)

Basic company analysis:QNCX - quincetx.com
Finished products of Quince

Investors are balancing the risk of capital loss against the expectation of high returns. The annual EPS growth trend measures the rate of earnings per share increase relative to the previous year, highlighting the issuer's lag behind industry averages. By analyzing the annual EPS change, one can assess the cost of hedging positions. This is critical for Quince Therapeutics (QNCX) during the integration of new drug delivery platforms. The market's wait-and-see attitude makes this metric an indicator of Dirk Tileman’s management efficiency.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Altimmune Corp - Net earnings per one share growth for the current year|Aardvark Therapeutics Inc (AARD) - Earnings per share growth in current year|Net earnings per share change in current year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth in current year|Net earnings per share growth this year Biomea Fusion (BMEA)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year